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Abstract 
Background: There is consistent evidence of a cumulative relationship between childhood 
adversity and psychosis, with number of adversities experienced increasing the probability of 
psychosis onset. It is possible that genetic factors moderate the association between 
childhood adversity and psychosis, potentially by influencing how an individual reacts 
biologically and/or psychologically following exposure to adversity, in such a way as to set 
them off on the path to psychosis. However, identifying the specific genetic variants involved 
and how they interact with childhood adversity remains challenging. We examined whether 
the association between cumulative exposure to childhood adversity and development of 
psychotic disorder was moderated by the COMT Val158Met, AKT1 rs2494732 or DRD2 
rs1076560 polymorphisms, known to affect dopamine levels.  
Methods: Participants were 285 first-presentation psychosis cases and 256 geographically-
matched controls drawn from the Genetics and Psychosis (GAP) study. Childhood adversity 
was assessed using the Childhood Experience of Care and Abuse Questionnaire (CECA.Q) 
and blood- and cheek-derived genotype data were collected. 
Results: Our findings revealed no main effect of COMT Val158Met, AKT1 rs2494732 and 
DRD2 rs1076560 polymorphisms on psychosis case status or reports of childhood adversity. 
Individuals reporting a history of multiple adversities were more likely to be psychosis 
patients than controls, regardless of their genetic risk. There was no evidence of candidate 
genotype by childhood adversity interactions in relation to psychosis onset.  
Conclusion: These findings did not provide evidence of a possible role of COMT Val158Met, 
AKT1 rs2494732 or DRD2 rs1076560 genotypes in modifying the association between 
childhood adversity and onset of psychosis.  
 
Keywords: AKT1, childhood trauma, COMT, DRD2, gene–environment, GxE, schizophrenia 
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1. Introduction 
 Exposure to adverse events in childhood is associated with around a 2 to 4-fold 
increased risk of psychosis (Morgan & Gayer-Anderson, 2016). Furthermore, childhood 
traumatic experiences tend to co-occur such that being exposed to one type of adversity 
increases the risk of exposure to another, with a cumulative effect of trauma on psychosis 
(Shevlin et al., 2008).  
However, very little is known about how exposure to childhood adversity is translated 
into biological risk for psychosis. One possibility is a gene-environment interaction, whereby 
a pre-existing genetic vulnerability modifies the biological response to adverse childhood 
experiences leading to the development of psychotic symptoms. We have previously 
explored whether genetic susceptibility to psychosis (via family history of psychosis and a 
polygenic risk score for schizophrenia) interacts with reported exposure to childhood 
adversity to predict onset of psychotic disorders but did not find any evidence for this (Trotta 
et al., 2015, 2016). Here we consider whether functionally-relevant polymorphisms might 
interact with adverse childhood experiences to lead to the development of psychosis. 
Specifically, dysregulation of the dopamine system has been found among individuals 
exposed to childhood adversity (De Bellis et al., 1999; Gerra et al., 2007; Heim et al., 2000; 
Pruessner et al., 2004) and is also postulated to be important in the pathogenesis of psychosis 
(Howes et al., 2009, 2017; Kapur, 2003; Moore et al., 1999; Spitzer, 1995; Walker & Diforio, 
1997; Walker et al., 2008). Therefore, genes involved in the regulation of dopamine levels in 
the brain would be plausible biological candidates for interaction with childhood adversity. 
Indeed several such genes, including Catechol-O-methyltransferase (COMT), AKT1 and the 
dopamine receptor type 2 (DRD2), have been linked with psychosis (Bolog et al., 2012; 
Cheng et al., 2006; Egan et al. 2001; Kapur et al., 1999; Karege et al., 2012; Li et al., 1996; 
Norton et al., 2007; Thiselton et al., 2008).  
4 
 
 The COMT gene plays an important role in the metabolism of dopamine in the central 
nervous system (Garris et al., 1993). A single nucleotide polymorphism (SNP) in the COMT 
gene, located on chromosome 22q11.2 (Winqvist et al., 1991), causes an amino acid change 
from valine to methionine at position 158 (Val158Met), with a 3- to 4-fold variation in 
enzymatic activity between Val/Val genotype and Met/Met genotype (Chen et al., 2004a; 
Weinshillboum et al., 1999). Specifically, Met/Met genotype carriers have the lowest COMT 
activity, whereas the Val/Val carriers have the most enzyme activity (Mannisto & Kaakkola, 
1999). Diverse gene-environment interactions have been reported for COMT Val158Met in 
moderating risk for psychotic disorder (Bilder et al., 2004; Tunbridge et al. 2006), for 
example, in the case of cannabis use in adolescence (Caspi et al., 2005; Henquet et al., 2009) 
and daily life stress (Peerbooms et al., 2012). Specifically, the Val allele has been associated 
with self-reported psychotic experiences in the context of stress and cannabis use in a Dutch 
adult population sample (Vinkers et al., 2013) and with the stress of army induction in a 
Greek male conscript sample (Stefanis et al., 2007). COMT Val158Met has also been 
associated with increased schizotypal personality trait scores in Val/Val individuals exposed 
to higher levels of childhood trauma (Savitz et al., 2010). Therefore, it seems a relevant 
candidate gene for testing in interaction with childhood adversity to predict the presence of 
psychotic disorders. 
Another candidate to test for a gene x childhood adversity interaction is the AKT1 
gene, located on chromosome 14q32, which has been reported to be associated with 
schizophrenia (Freyberg et al., 2010; Mathur et al., 2010). AKT1 codes for a protein kinase 
(Protein kinase B, PKB), that forms an integral part of a cascade mediating dopamine 
signalling in the striatum. Animal and human studies have found that psychosocial stress, 
including childhood adversity, leads to a sensitization of mesostriatal dopamine 
neurotransmission, which might increase the risk of developing psychotic symptoms (Egerton 
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et al., 2016; Howes et al., 2004). Moreover, a GxE interaction has been reported between an 
AKT1 gene polymorphism, rs2494732, and an environmental risk factor, cannabis use, in the 
pathogenesis of psychosis: carriers of the C/C genotype were most likely to develop 
psychotic illness after smoking cannabis (Di Forti et al., 2012; van Winkel et al., 2011a, 
2011b). To date, no studies have investigated an AKT1 gene x childhood adversity interaction 
in psychosis onset, though a pilot study focusing on the potential relationship of stress and 
psychosis showed that higher subclinical psychotic experiences were associated with chronic 
and severe stress and AKT1 rs2494732 in a sample of students (Bruenig et al., 2014). 
A third potentially relevant SNP is rs1076560 in the DRD2 gene (chromosome 
11q23), located within intron 6, which has been found to be associated with schizophrenia 
(Ripke et al., 2014). This SNP specifically regulates the expression of the dopamine receptor 
long (D2L) and short (D2S) isoforms, responsible for dopamine synthesis and release in the 
frontal cortex (Zhang et al., 2007). In line with previous research on AKT1, the role of the 
DRD2 gene has only been investigated in the context of the association between cannabis use 
and psychosis, with subjects carrying the T risk allele showing an increased risk of having a 
psychotic disorder in the context of cannabis use compared to GG carriers (Colizzi et al., 
2015a; 2015b). 
We used a first-presentation psychosis case-control sample to investigate whether the 
association between cumulative exposure to childhood adversity and development of 
psychotic disorder was moderated by the COMT Val158Met, AKT1 rs2494732 and DRD2 
rs1076560 polymorphisms, as these have been shown to be involved in the regulation of 
dopamine and linked to psychosis. Of the selected candidate genes, only DRD2 elicits 
genome-wide support for a role in the pathogenesis of schizophrenia (Ripke et al., 2014), 
although this does not preclude the potential involvement of all three genes in the moderation 
of childhood adversity, an exposure whose genetic basis has not yet been interrogated on a 
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genomic scale. Therefore, we investigated each candidate gene separately in interaction with 
childhood adversity to explore whether there were specific moderating effects of the selected 
polymorphisms on the presence of psychotic disorder. 
 
2. Methods 
2.1. Sample 
The sample was drawn from first-presentation psychosis cases from the Lambeth, 
Southwark, Lewisham, and Croydon adult in-patient and out-patient units of the South 
London & Maudsley (SLAM) Mental Health National Health Service (NHS) Foundation 
Trust and unaffected community controls who participated in the Genetics and Psychosis 
(GAP) study (Di Forti et al, 2015). Participants from this study were included if they had 
been assessed regarding childhood adversity and provided an analysable sample of DNA. 
Inclusion criteria for cases were: aged 18–65 years, presenting to psychiatric services for the 
first time with a psychotic disorder (codes F20–29 and F30–33 from the International 
Classification of Diseases [ICD-10]; World Health Organization, 1992), and resident within 
tightly defined catchment areas in Southeast London, UK. Exclusion criteria were: organic 
psychosis; intelligence quotient (IQ) under 70; previous contact with services for psychosis, 
and transient psychotic symptoms resulting from acute intoxication.  
Controls were aged 18–65 years and recruited from the local population living in the 
area served by the Trust. Efforts were made to obtain a control sample that was representative 
of the general population in age, gender, ethnicity, educational qualifications, and 
employment status. The Psychosis Screening Questionnaire (PSQ; Bebbington and Nayani, 
1995) was administered to all potential control group participants; individuals were excluded 
if they met criteria for a psychotic disorder. 
7 
 
2.2. Measures 
2.2.1. Childhood adversity 
The Childhood Experience of Care and Abuse Questionnaire (CECA.Q; Bifulco et al., 
2005) was employed to retrospectively elicit information on a range of adverse childhood 
experiences from participants. Physical abuse by the main mother and father figures (usually, 
but not necessarily, the biological parents), sexual abuse by any adult or an individual at least 
5 years older than the recipient, separation from a parent for at least 6 months, death of a 
parent, taken into institutional care, and disrupted family arrangements, all prior to 17 years 
of age, were assessed. The CECA.Q was read out to all participants during face-to-face 
interviews to improve the accuracy of the fixed category responses obtained. This 
questionnaire has been shown to have good internal consistency (Smith et al., 2002), 
satisfactory levels of test-retest reliability over 7 years in a similar psychosis sample (Fisher 
et al., 2011), and reasonable concurrent validity with other measures (Bifulco et al., 2005; 
Fisher et al., 2011; Smith et al., 2002).  
 
2.3. Genotyping procedures 
Seventy-five percent of DNA samples used originated from blood and 25% from 
cheek swabs. A comparison of genotype results for 360 individuals with overlapping blood 
and cheek swab DNA revealed there was 100% concordance between blood- and cheek-
derived genotype data (Di Forti et al., 2015). The DNA was extracted using a standard 
phenol-chloroform extraction procedure. A Taqman SNP assay was used to genotype the 
COMT gene at the rs4680 locus, the AKT1 gene at the rs2494732 locus, and DRD2 at the 
rs1076560 locus (kit format at http://www.appliedbiosystems.com). After an initial Taq 
polymerase activation/DNA denaturation step, samples were subjected to PCR reaction 
following standard Applied Biosystem dry DNA protocol. Amplification products were 
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analyzed using the Applied Biosystems 7900HT Fast Real-time PCR System. Genotype calls 
were made based on a clustering algorithm with quality value of 95%. 
 
2.3.1. Validation of self-reported ethnicity 
To confirm self-report of ethnicity, genetic ancestry was derived using a panel of 57 
ancestry informative genetic markers. These were genotyped using iPLEX technology 
developed for the MassArray platform (Sequenom Inc., San Diego, California) and an 
ancestry score was derived using the program Structure (Falush et al., 2003) to implement a 
model-based (Markov Chain Monte Carlo) clustering algorithm. Individuals who scored 
between 96% and 100% for genetic cluster membership were used to create a three-way 
ancestral axis based on Black African, European Caucasian, and Asian ancestry. These 
reference groups were used to index genetic ancestry for the remaining sample. Eighty-nine 
percent of participants had information on both self-reported ethnicity and ancestry markers. 
The level of overall agreement between self-reported and genetic ethnicities (96%) was 
reassuringly high. 
 
2.4. Ethics 
This study was part of the GAP study, which was granted ethical approval by the South 
London and Maudsley and Institute of Psychiatry Local Research Ethics Committee (REF: 
05/Q0706/158). All cases and controls included in the study gave informed written consent to 
the publication of data originating from the study. 
2.5. Data analysis 
Data were analyzed using Stata 11 (Stata, College Station, Texas). A composite 
variable was computed to summarize how many of the different adversities had been 
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experienced by each individual, following the guidelines published by Bifulco et al. (2005). 
This ‘total adversity’ score involved summing the dichotomous CECA.Q severity subscale 
scores (range 0-6) and then recoding the total into an ordinal scale of 0 (none), 1 (single 
adverse experience), and 2 (multiple adverse experiences).  
For COMT Val158Met polymorphism, the number of Val alleles and genotypes were 
coded as 0 (no Val alleles, Met/Met genotype), 1 (one Val allele, Val/Met genotype), and 2 
(two Val alleles, Val/Val genotype). The AKT1 gene (rs2494732) was coded as 0 (no risk 
alleles, TT genotype), 1 (one risk allele, C/T genotype), and 2 (two risk alleles, C/C genotype). 
The DRD2 gene (rs1076560) was coded as 0 (no risk alleles, G/G genotype), 1 (one risk 
allele, G/T genotype), and 2 (two risk alleles, T/T genotype).  
Cuzick’s (1985) non-parametric test of trend for ranks across ordered groups was 
performed using the ‘nptrend’ command in STATA to assess associations with psychosis and 
childhood adversity across the COMT, AKT1 and DRD2 genotypes. This test is considered 
more sensitive to trends across three or more categories than the standard chi-square test and 
is also robust to deviations from Hardy Weinberg Equilibrium (HWE) (Cuzick, 1985). The 
results of this trend test were used to assess the presence of gene-environment correlations 
between COMT, AKT1, DRD2 genotypes and total childhood adversities in psychosis cases 
and controls. The main associations and interactions between childhood adversity and COMT, 
AKT1 and DRD2 genotypes on the presence/absence of psychosis were tested using a 
generalized linear model with the binomial distribution and identity link function specified 
(Wacholder, 1986) to estimate risk differences (RD) and 95% confidence intervals (CI). We 
tested for interaction with an additive model as it has been argued to be more in line with 
biological interaction (Knol et al., 2007). All analyses were adjusted for proportion of black 
genetic ancestry. GxE interaction analyses were conducted firstly with additive genetic 
models and then using dominant and recessive genetic models for full transparency. COMT 
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Val158Met genetic models were coded as follows: additive (0=Met/Met, 1=Val/Met, 
2=Val/Val)), dominant (0=Met/Met, 1=Val/Met or Val/Val), and recessive (0=Met/Met or 
Val/Met, 1=Val/Val). AKT1 rs2494732 genetic models were coded as follows: additive: 
(0=TT, 1=C/T, 2=C/C), dominant (0=TT, 1=C/T or C/C), and recessive (0=TT or C/T, 1=C/C). 
DRD2 rs1076560 genetic models were coded as follows: additive: (0=G/G, 1=G/T, 2= T/T), 
dominant (0= G/G, 1=G/T or T/T), and recessive (0= G/G or G/T, 1= T/T). 
 
3. Results 
3.1. Sample characteristics 
Information on number of childhood adversities was available for 285 first-
presentation psychosis patients and 256 unaffected controls. Those who completed the 
CECA.Q did not differ significantly from non-completers in terms of gender (cases: 
χ²=3.757, p=0.055; controls: χ²=0.658, p=0.445), but controls who completed the 
questionnaire were more often of non-White ethnicity (controls: χ²=8.119, p=0.017 cases: 
χ²=1.368, p=0.500) and significantly younger than the rest of the GAP sample (controls: 
mean age 29 vs. 32.8 years, t=3.183, p=0.002; cases: t=-1.705, p=0.089). However, in 
practice this was only an average of 4 years difference in age which should not have had a 
significant impact on memory of past events (Fisher et al., 2011).  
The demographic characteristics of the sample and the main association between 
number of childhood adversities in cases and controls are provided in Supplementary Table 1. 
Psychosis cases had a lower level of education (χ²=32.60, p<0.001), and were more often of 
non-White ethnicity (χ²=76.73, p<0.001) compared with controls, and thus we controlled for 
these variables in the subsequent analyses. There was no significant difference between 
psychosis cases and controls in terms of gender (χ²=2.57, p=0.065) and age (t= 0.342, 
p=0.733). Total number of childhood adversities experienced was associated with having a 
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psychotic disorder (z= 4.97, p<0.001), with first-presentation psychosis patients more than 
twice as likely as controls to report exposure to one (Adjusted OR=2.01, 95% CI 1.30-3.11, 
p=0.002) or multiple (Adjusted OR=2.17, 95% CI 1.31-3.61, p=0.003) childhood adversities. 
Table 1 shows the distribution of the COMT Val158Met, AKT1 rs2494732, and DRD2 
rs1076560 genotypes in cases and controls along with the findings of the Hardy-Weinberg 
Equilibrium (HWE) tests. The COMT genotypes were in HWE amongst controls (χ²=2.881, 
p=0.089), however in the cases the HWE was breached (p=0.034). The distribution of the 
COMT genotypes was similar between psychosis cases and controls and this was confirmed 
by a non-significant result for Cuzick’s non-parametric trend test (z=0.46, p=0.645). The 
AKT1 rs2494732 polymorphism allele was in HWE amongst both cases (χ²=0.525, p=0.468) 
and controls (χ²=0.030, p=0.864). There was no main association between the AKT1 
rs2494732 polymorphism and psychosis in this sample (z=0.32, p=0.748). Similarly, the 
DRD2 genotypes were in HWE amongst cases (χ²=0.009, p=0.923) and controls (χ²=0.017, 
p=895), and there was a non-significant result for Cuzick’s non-parametric trend test (z=-0.95, 
p=0.341) indicative of no association between DRD2 rs1076560 and psychosis status in this 
sample. 
 
3.2 Gene-environment correlation  
The proportion of participants with each genotype was compared for those with and 
without a history of childhood adversity (Table 2). There was no significant difference in the 
number of childhood adversities reported by COMT genotype amongst cases (z=1.05, 
p=0.292) or controls (z=1.07, p=0.283). Similarly, no significant gene-environment 
correlations were found overall between the AKT1 genotype and childhood adversity amongst 
cases (z=-0.96, p=0.338) or controls (z=1.50, p=0.134), as well as between DRD2 genotype 
and childhood adversity in cases (z=-1.35, p=0.176) or controls (z=0.67, p=0.503). 
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3.3. Genotype by childhood adversity interaction in psychosis 
Table 3 presents the main effects of the total number of childhood adversities and 
their interactions with COMT, AKT1 and DRD2 additive genetic models on the presence of 
psychosis. The total number of adversities was associated with psychosis regardless of 
COMT, AKT1 and DRD2 genotypes (all p’s<0.05). No significant interactions with 
childhood adversity were found under an additive genetic model in all the polymorphisms (all 
p’s>0.05). Additionally, no significant interactions were found for multiple adversities with 
COMT, AKT1 and DRD2 under dominant or recessive genetic models (Supplementary Table 
2). 
 
4. Discussion  
No main associations between the selected polymorphisms and psychosis case status 
or childhood adversity were found in this sample. This is in line with previous findings on 
COMT Val158Met which have been inconsistent (Glatt et al., 2003) and even a large family-
based study found only modest associations between this variant and schizophrenia (Chen et 
al., 2004b). Moreover, recent meta-analyses concluded that there was no, or at best only weak, 
evidence of COMT genotype increasing risk for psychosis (Fan et al., 2005; Munafo et al., 
2005; Ripke et al., 2013). Our findings on AKT1 rs2494732 polymorphism and psychotic 
disorder in this sample are in contrast with some previous studies that found an association 
between this candidate gene and schizophrenia (Bolog et al., 2012; Karege et al., 2012; 
Norton et al., 2007; Thiselton et al., 2008). Furthermore, despite the DRD2 gene being 
identified in a recent genome-wide association study (Ripke et al., 2013) as a risk gene for 
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schizophrenia, our results did not support this finding in a more broadly defined psychotic 
disorder sample. 
There was, as expected, a main association between total number of adverse 
childhood experiences and presence of psychotic disorder but this occurred regardless of 
genotype for the polymorphisms studied. This is in line with our previous paper that showed 
an association between childhood adversity and psychosis onset, regardless of schizophrenia 
polygenic risk score (Trotta et al., 2016). However, it is in contrast to previous studies that 
have shown the greatest impact of stressful events on psychotic symptoms amongst 
individuals with at least one COMT Val allele compared to those homozygous for the Met 
allele (Simons et al., 2009; Stefanis et al., 2007), although other studies have found greater 
sensitivity for the Met/Met genotype (Myin-Germeys et al., 2006; van Winkel et al., 2008a). 
This discrepancy could be partly due to differences in the demographics of the samples, type 
of psychotic outcome or intensity of the stressors studied (Simons et al., 2009; van Winkel et 
al., 2008b) more than the specific alleles.  
Disruptions in postnatal rearing conditions can lead to profound and lasting changes 
in the responsiveness of mesocorticolimbic dopamine neurons to stress in animals (Brake et 
al, 2004; Hall et al., 1999; Pani et al., 2000) as well as in humans (Collip et al., 2008; 
Pruessner et al, 2004). According to the social defeat hypothesis, long-term exposure to the 
experience of social defeat or social exclusion may lead to sensitization of the mesolimbic 
dopamine system (and/or increased baseline activity of this system) and thereby increase the 
risk for schizophrenia (Cao et al., 2010; Selten et al., 2013; van Nierop et al., 2014b). 
Therefore, exposure to childhood adversity might lead to dysfunctional emotional responses 
(e.g. greater anticipation of threatening events) (Freeman et al., 2013; Bentall et al., 2014) 
which in turn are associated with an anomalous dopaminergic response (Deutch et al., 1990), 
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facilitating the onset of psychotic symptoms (Goto et al., 2007; Kapur, 2003; Kapur et al., 
2005).  
 There was no evidence of genotype by childhood adversity interactions for presence 
of psychotic disorder. These results are in line with a previous study which found no 
interaction between COMT Val158Met genotype and childhood maltreatment in predicting 
schizophreniform disorder at 26 years of age (Caspi et al., 2005). However, previous animal 
studies have shown an interaction between COMT and maternal care in mice (Zhang et al., 
2005). A three-way interaction between the COMT genotype Val alleles, childhood 
maltreatment, and adolescent cannabis use has also been reported in the etiology of psychotic 
experiences (Alemany et al., 2013; Vinkers et al., 2013). Similarly, previous studies found an 
interaction between AKT1 rs2494732 and DRD2 rs1076560 with cannabis use in first-
episode psychosis (Di Forti et al., 2012; van Winkel et al., 2011b; Colizzi et al. 2015a; 
2015b). Therefore, it might be that the lack of an interaction effect between COMT, AKT1, 
DRD2 and childhood adversity on psychosis in the current sample could be due to other 
environmental factors influencing psychosis case status.  
 
4.1 Limitations 
It is important to consider the current findings in light of several limitations. The most 
important consideration in this regard is low a priori probability of interaction and/or low 
statistical power (Duncan & Keller, 2011), issues that are more common in candidate gene 
approaches (Burton et al., 2009). Our results should thus be interpreted with caution. 
Although these findings need to be replicated in a larger-scale study, we have previously 
shown in the same sample that DRD2 and AKT1 polymorphisms interact in increasing the 
risk of psychosis in cannabis users compared to non-users (Colizzi et al., 2015b). Therefore, 
our negative findings could suggest that other environmental factors might be interacting 
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with the dopamine genetic pathway, such as substance use (Di Forti et al., 2012) or stressful 
life events occurring in adulthood (Beards et al., 2013), to lead to the development of 
psychosis. Furthermore, this study may have failed to detect an interaction also because of 
the utilization of retrospective self-report measures (i.e. CECA-Q; Bifulco et al., 2005).  
Moreover, this sample was multiethnic. This may be important in light of the 
differences in allele frequency across the main ethnic groups (African and European origin; 
Knowler et al., 1988). However, to account for the possibility of population stratification, all 
analyses were controlled for the potential confounding effect of genetic ancestry to reduce 
this potential bias in the results. In this sample, one SNP was also in Hardy–Weinberg 
disequilibrium. As SNPs in Hardy–Weinberg disequilibrium are less powerful, and do not 
tend to increase false-positive results (Fardo et al., 2009), the reported results are unlikely to 
be caused by Hardy–Weinberg disequilibrium, especially given the absence of quality control 
issues (the genotypes were successfully identified at call rates of between 79% and 85%).  
We also chose to focus on functionally-relevant candidate genes as we previously 
found no interaction with childhood adversity and a schizophrenia PRS in relation to 
psychosis (Trotta et al., 2016). However, this approach also has limitations. One potential 
way to overcome the limitations from both single candidate gene and PRS studies would be 
to identify co-expression pathways of risk genes in schizophrenia (Harrison & Weinberger, 
2005). Because genes interact with each other and are co-regulated by a common biological 
process (e.g., mRNA), the investigation of gene pathways has been argued to have greater 
biological validity than single gene and PRS approaches (Mitra et al., 2010). For instance, 
Weighted Gene Co-expression Network Analysis (WGCNA) integrates information related to 
multiple genes and identifies clusters of co-expressed genes based on similar genetic profiles 
across individuals (Monaco et al., 2018). Recent findings have, for example, identified a 
cluster for the DRD2 pathway prefrontal co-expression, which has been found to be 
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associated with greater prefrontal activity and working memory impairment in schizophrenia 
(Pergola et al., 2017). Therefore, the identification of specific molecular pathways could 
improve the understanding of the genetic factors related with psychotic disorders and should 
be explored in interaction with childhood adversity and other environmental factors in future 
studies. 
 In conclusion, the current study did not provide evidence of an interaction between 
specific candidate genes and childhood adversity in psychosis onset and, therefore, in this 
particular sample, the specific genotypes involved in the dopamine pathway did not seem to 
moderate the effect of adverse childhood experiences on presence of psychotic disorder. 
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Table 1 
Hardy-Weinberg Equilibrium results for COMT, AKT1 and DRD2 genotypes in psychosis cases and unaffected 
controls 
 
Genotype Cases  
n (%) 
Controls  
n (%) 
COMT Val158Met   
Val/Val 96 (38.4) 74 (36.8) 
Val/Met 130 (52) 105 (52.2) 
Met/Met 24 (9.6) 22 (10.9) 
HWE X2= 4.493, p=0.034 X2= 2.881, p=0.089 
AKT1 rs2494732    
C/C 54 (22) 43 (22.5) 
C/T 128 (52.2) 94 (49.2) 
T/T 63 (25.7) 54 (28.3) 
HWE X2= 0.525, p=0.468 X2= 0.030, p=0.864 
DRD2 rs1076560    
T/T 3 (1.2) 3 (1.5) 
G/T 47 (19.1) 44 (22.6) 
G/G 196 (79.7) 148(75.9) 
HWE X2=0.009, p=0.923 X2=0.017, p=0.895 
HWE, Hardy-Weinberg Equilibrium. Met, methionine. Val, valine. 
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Table 2 
Distribution of COMT, AKT1 and DRD2 genotypes by history of childhood adversity in psychosis cases and unaffected controls 
Total adversity  Cases   Controls   
COMT Val158Met Val/Val 
n (%) 
Val/Met 
n (%) 
Met/Met 
n (%) 
 
Z 
 
P 
Val/Val 
n (%) 
Val/Met 
n (%) 
Met/Met 
n (%) 
 
Z 
 
P 
 
   1.05 0.292    1.07 0.283 
2 or more adversities 30 (40.5) 37 (50.0) 7 (9.5)   14 (40.0) 20 (57.1) 1 (2.9)   
1  42 (38.5) 61 (56.0) 6 (5.5)   23 (37.1) 32 (51.6) 7 (11.3)   
0  24 (35.8) 32 (47.8) 11 (16.4)   37 (35.6) 53 (51.0) 14 (13.4)   
 
AKT1 rs2494732 
 
C/C 
n (%) 
 
C/T 
n (%) 
 
T/T 
n (%) 
 
 
 
 
 
C/C 
n (%) 
 
C/T 
n (%) 
 
T/T 
n (%) 
 
 
 
 
    -0.96 0.338    1.50 0.134 
2 or more adversities 14 (19.2) 37 (50.7) 14 (30.1)   5 (14.7) 12 (35.3) 17 (50.0)   
1  24 (22.2) 59 (54.6) 25 (23.2)   10 (16.4) 28 (45.9) 23 (37.7)   
0  16 (25.0) 32 (50.0) 16 (25.0)   6 (6.2) 47 (49.0) 43 (44.8)   
 
DRD2 rs1076560 
 
T/T 
n (%) 
 
G/T 
n (%) 
 
G/G 
n (%) 
 
 
 
 
 
T/T 
n (%) 
 
G/T 
n (%) 
 
G/G 
n (%) 
 
 
 
 
    
-1.35 0.176 
   
0.67 0.503 
2 or more adversities 1 (1.3) 13 (17.6) 60 (81.1)   1 (2.9) 7 (20.6) 26 (76.5)   
1  0 (0.0) 18 (16.7) 90 (83.3)   1 (1.7) 16 (26.2) 44 (72.1)   
0  2 (3.1) 16 (25.0) 46 (71.9)   1 (1.0) 21 (21.0) 78 (78.0)   
Met, methionine. Val, valine. 
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Table 3 
Main associations and additive interactions between total childhood adversities, COMT Val158Met, AKT1 rs2494732, and DRD2 rs1076560 genotypes on the presence of 
psychotic disorder 
Total childhood adversity Unadjusted RD 95% CI P value Adjusted RD* 95% CI P value 
COMT Val158Met 
 
 
  
 
 
Overall sample (n=451) 0.14 0.08-0.19 <0.001 0.09 0.03-0.15 0.003 
Additive GxE interaction -0.02 -0.11-0.06 0.614 -0.03 -0.09-0.04 0.390 
 
 
 
  
 
 
AKT1 rs2494732 
 
 
  
 
 
Overall sample (n=436) 0.13 0.07-0.19 <0.001 0.14 0.08-0.19 <0.001 
Additive GxE interaction -0.05 -0.13-0.02 0.181 -0.05 -0.13-0.03 0.187 
       
DRD2 rs1076560 
 
 
  
 
 
Overall sample (n=441) 0.13 0.08-0.19 <0.001 0.09 0.03-0.15 0.003 
Additive GxE interaction -0.06 0.09-0.22 0.340 -0.05 -0.18-0.07 0.384 
*Adjusted for gender, education level, age at interview, and proportion of black genetic ancestry. CI, confidence interval. GxE, genetic by environmental interaction. RD, risk difference. Figures 
in bold indicate p<0.05. 
 
